Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Tan

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
Breast Cancer Research and Treatment|October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapySara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneLinda T Vahdat, Brian Pruitt, Carol J Fabian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
The Lancet. Psychiatry|September 28, 2023
International consensus on patient-centred outcomes in eating disordersAmelia Austin, Umanga De Silva, Christiana Ilesanmi, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
Breast Cancer Research and Treatment|October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapySara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneLinda T Vahdat, Brian Pruitt, Carol J Fabian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
The Lancet. Psychiatry|September 28, 2023
International consensus on patient-centred outcomes in eating disordersAmelia Austin, Umanga De Silva, Christiana Ilesanmi, et al.
Pageof 4